Lenacapavir,targeting the human immunodeficiency virus type-1(HIV-1)capsid,is the first-in-class antiretroviral drug recently approved for clinical use.The development of Lenacapavir is attributed to the remarkable progress in our understanding of the capsid protein made during the last few years.Considered little more than a component of the virus shell to be shed early during infection,capsid has been found to be a key player in the HIV-1 life cycle by interacting with multiple host cell factors,entering the nucleus,and directing integration.Here,we describe the key advances that led to this'capsid revolution'.
HIV-1 capsid
Ian A.Taylor、Ariberto Fassati
展开 >
Macromolecular Structure Laboratory,The Francis Crick Institute,London NW1 1AT,UK
Division of Infection and Immunity,University College London,London WC1E 6JF,UK
Institute of Immunity and Transplantation,University College London,London NW3 2QG,UK
UK Medical Research CouncilCanadian Institute of Health ResearchFrancis Crick Institute(to I.A.T.)core funding from Cancer Research UK
NETL
NSTL
万方数据
